サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1784076

組み換えタンパク質の世界市場

Recombinant Proteins

出版日
ページ情報
英文 214 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
組み換えタンパク質の世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 214 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

組み換えタンパク質の世界市場は2030年までに58億米ドルに達する見込み

2024年に33億米ドルと推定される組み換えタンパク質の世界市場は、分析期間2024-2030年にCAGR 10.2%で成長し、2030年には58億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるサイトカイン・成長因子は、CAGR 11.4%を記録し、分析期間終了時には17億米ドルに達すると予測されます。抗体分野の成長率は、分析期間を通じてCAGR 11.0％と推定されます。

米国市場は8億5,710万米ドルと推定、中国はCAGR9.8%で成長すると予測

米国の組み換えタンパク質市場は、2024年には8億5,710万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 9.8%で推移し、2030年には予測市場規模9億2,550万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.5％と8.6％と予測されています。欧州では、ドイツがCAGR約8.1%で成長すると予測されています。

世界の組み換えタンパク質市場- 主要動向と促進要因のまとめ

なぜ組み換えタンパク質が生物医学研究と治療法を変革するのか？

組み換えタンパク質は、様々な用途に高純度、スケーラブル、標的タンパク質のソリューションを提供することにより、生物医学研究と治療開発に革命をもたらしました。細菌、酵母、哺乳類細胞、植物ベースのシステムなどの宿主細胞で遺伝子工学によって生産されるこれらのタンパク質は、創薬、ワクチン生産、診断、個別化医療において不可欠です。がん、自己免疫疾患、遺伝性疾患などの慢性疾患の増加により、モノクローナル抗体、成長因子、酵素補充療法など、組換えタンパク質ベースの治療に対する需要が高まっています。さらに、合成生物学とタンパク質工学の進歩により、安定性と生物活性を向上させた、高度に特異的で最適化された組み換えタンパク質の開発が可能になりました。バイオ製薬会社が生物学的製剤のパイプラインを拡大し、研究機関が精密医療に重点を置く中、組み換えタンパク質は治療と診断のイノベーションを推進する上で極めて重要な役割を果たし続けています。

技術の進歩は組換えタンパク質生産をどのように強化しているか？

組換えタンパク質市場は、発現システム、精製技術、製剤戦略の革新から大きな恩恵を受けています。哺乳類細胞培養システム、特にCHO（チャイニーズハムスター卵巣）細胞の導入は、ヒトの生物学的機能に忠実な複雑なグリコシル化タンパク質の生産を向上させました。CRISPR-Cas9遺伝子編集を含む細胞株工学の進歩は、タンパク質の収量、安定性、一貫性をさらに向上させました。連続バイオプロセス技術とシングルユース・バイオリアクターは、大規模生産を合理化し、製造コストを削減し、汚染リスクを最小限に抑えています。さらに、AIを駆使したタンパク質モデリングと計算生物学は、治療効果を高め、免疫原性を低減した組み換えタンパク質の合理的な設計を可能にしています。このような技術的な飛躍的進歩により、組換えタンパク質の生産はより効率的で拡張性があり、新たな治療ニーズにも適応できるようになっています。

どのような市場動向が組換えタンパク質産業の拡大を牽引しているのか？

生物製剤や標的療法への依存の高まりにより、医薬品、農業、産業バイオテクノロジーなど様々な分野で組み換えタンパク質に対する需要が大幅に増加しています。COVID-19のパンデミックは、組み換えタンパク質ベースの抗原とアジュバントを利用したmRNAワクチンにより、ワクチン開発における組み換えタンパク質の重要性をさらに強調しました。さらに、個別化医療の台頭により、特定の患者の遺伝子プロファイルに合わせた組み換えタンパク質の需要が高まり、治療の精度と有効性が向上しました。また、バイオシミラーやバイオベッターの拡大も、企業がブランド生物製剤に代わる費用対効果の高い代替品を求めていることから、市場の成長に寄与しています。さらに、細胞培養サプリメント、分子生物学ツール、バイオマーカー探索などの研究用途における組み換えタンパク質の使用の増加が、市場導入をさらに促進しています。ライフサイエンス産業が進化し続ける中、組み換えタンパク質はヘルスケアとバイオテクノロジーにおけるイノベーションの鍵となる存在であり続けています。

組み換えタンパク質市場の主な成長促進要因は？

世界の組み換えタンパク質市場の成長は、発現システム技術の進歩、生物製剤や標的療法に対する需要の高まり、バイオ医薬品の研究開発への投資の増加など、いくつかの要因によって牽引されています。細胞培養や治療用途に組み換えタンパク質を利用する細胞療法や遺伝子療法の拡大が、市場の成長をさらに促進しています。さらに、ハイスループットタンパク質スクリーニング技術やAI主導の創薬プラットフォームの採用が拡大しており、組換えタンパク質ベースの治療薬の開発パイプラインが強化されています。迅速な生物学的製剤の承認に向けた規制当局の支援と相まって、費用対効果が高くスケーラブルなバイオ製造ソリューションへのシフトも市場拡大に寄与しています。タンパク質工学とバイオプロセス最適化の継続的な進歩により、組み換えタンパク質市場は持続的な成長を遂げ、医療、研究、産業バイオテクノロジーにおけるブレークスルーを促進すると予想されます。

セグメント

製品（サイトカイン・成長因子、抗体、免疫チェックポイントタンパク質、ウイルス抗原、酵素、組換え制御タンパク質、ホルモン、その他製品）、宿主細胞（哺乳類系、細菌細胞、酵母・真菌、昆虫細胞、その他宿主細胞）、用途（治療薬用途、研究開発用途、研究用途、その他用途）、最終用途（製薬・バイオテクノロジー企業最終用途、学術・研究機関最終用途、診断機関最終用途、その他最終用途）

調査対象企業の例

  • Abcam plc
  • Abnova Corporation
  • ACROBiosystems
  • Amgen Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Eli Lilly and Company
  • Enzo Life Sciences, Inc.
  • GenScript Biotech Corporation
  • Merck KGaA
  • Miltenyi Biotec
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Proteintech Group, Inc.
  • RayBiotech Life Inc.
  • Sanofi S.A.
  • Sino Biological Inc.
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32765

Global Recombinant Proteins Market to Reach US$5.8 Billion by 2030

The global market for Recombinant Proteins estimated at US$3.3 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 10.2% over the analysis period 2024-2030. Cytokines & Growth Factors, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Antibodies segment is estimated at 11.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$857.1 Million While China is Forecast to Grow at 9.8% CAGR

The Recombinant Proteins market in the U.S. is estimated at US$857.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$925.5 Million by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Global Recombinant Proteins Market - Key Trends & Drivers Summarized

Why Are Recombinant Proteins Transforming Biomedical Research and Therapeutics?

Recombinant proteins have revolutionized biomedical research and therapeutic development by offering high-purity, scalable, and targeted protein solutions for various applications. These proteins, produced through genetic engineering in host cells such as bacteria, yeast, mammalian cells, and plant-based systems, are essential in drug discovery, vaccine production, diagnostics, and personalized medicine. The increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and genetic conditions has fueled demand for recombinant protein-based treatments, including monoclonal antibodies, growth factors, and enzyme replacement therapies. Additionally, advancements in synthetic biology and protein engineering have enabled the development of highly specific and optimized recombinant proteins with improved stability and bioactivity. With biopharmaceutical companies expanding their biologic pipelines and research institutions focusing on precision medicine, recombinant proteins continue to play a pivotal role in advancing therapeutic and diagnostic innovations.

How Are Technological Advancements Enhancing Recombinant Protein Production?

The recombinant protein market has benefited significantly from innovations in expression systems, purification techniques, and formulation strategies. The introduction of mammalian cell culture systems, particularly CHO (Chinese hamster ovary) cells, has improved the production of complex glycosylated proteins with high fidelity to human biological functions. Advances in cell-line engineering, including CRISPR-Cas9 gene editing, have further enhanced protein yield, stability, and consistency. Continuous bioprocessing techniques and single-use bioreactors have streamlined large-scale production, reducing manufacturing costs and minimizing contamination risks. Furthermore, AI-driven protein modeling and computational biology are enabling the rational design of recombinant proteins with enhanced therapeutic efficacy and reduced immunogenicity. These technological breakthroughs are making recombinant protein production more efficient, scalable, and adaptable to emerging therapeutic needs.

What Market Trends Are Driving the Expansion of the Recombinant Protein Industry?

The growing reliance on biologics and targeted therapies has significantly increased demand for recombinant proteins across various sectors, including pharmaceuticals, agriculture, and industrial biotechnology. The COVID-19 pandemic further underscored the importance of recombinant proteins in vaccine development, with mRNA vaccines utilizing recombinant protein-based antigens and adjuvants. Additionally, the rise of personalized medicine has driven demand for recombinant proteins tailored to specific patient genetic profiles, enhancing treatment precision and effectiveness. The expansion of biosimilars and biobetters has also contributed to market growth, as companies seek cost-effective alternatives to branded biologics. Moreover, the increasing use of recombinant proteins in research applications, such as cell culture supplements, molecular biology tools, and biomarker discovery, is further driving market adoption. As the life sciences industry continues to evolve, recombinant proteins remain a key enabler of innovation in healthcare and biotechnology.

What Are the Key Growth Drivers of the Recombinant Proteins Market?

The growth in the global recombinant proteins market is driven by several factors, including advancements in expression system technology, rising demand for biologics and targeted therapies, and increasing investments in biopharmaceutical R&D. The expansion of cell and gene therapies, which rely on recombinant proteins for cell culture and therapeutic applications, has further fueled market growth. Additionally, the growing adoption of high-throughput protein screening techniques and AI-driven drug discovery platforms is enhancing the development pipeline for recombinant protein-based therapeutics. The shift toward cost-effective and scalable biomanufacturing solutions, coupled with regulatory support for expedited biologic approvals, is also contributing to market expansion. With continued advancements in protein engineering and bioprocess optimization, the recombinant proteins market is expected to experience sustained growth, driving breakthroughs in medicine, research, and industrial biotechnology.

SCOPE OF STUDY:

The report analyzes the Recombinant Proteins market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones, Other Products); Host Cell (Mammalian systems, Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells); Application (Therapeutics Application, Drug Discovery & Development Application, Research Application, Other Applications); End-Use (Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Abcam plc
  • Abnova Corporation
  • ACROBiosystems
  • Amgen Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Eli Lilly and Company
  • Enzo Life Sciences, Inc.
  • GenScript Biotech Corporation
  • Merck KGaA
  • Miltenyi Biotec
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Proteintech Group, Inc.
  • RayBiotech Life Inc.
  • Sanofi S.A.
  • Sino Biological Inc.
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Recombinant Proteins - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Pipeline of Biologic Drugs and Biosimilars Drives Demand for Recombinant Proteins
    • Rise in Cell and Gene Therapy Applications Expands Addressable Market for Recombinant Protein Inputs
    • Increasing Demand for Targeted Therapeutics Throws the Spotlight on Engineered Protein Molecules
    • Expansion of Protein-Based Vaccines Strengthens Business Case for Recombinant Antigen Production
    • Rapid Advances in Protein Expression Systems Propel Innovation in Yield and Functionality
    • Growth in Diagnostic and Research Use Cases Accelerates Demand for Labeled and Tagged Proteins
    • Use of Recombinant Proteins in Regenerative Medicine Spurs Market for Cell Culture-Grade Variants
    • Improved Stability and Specificity of Recombinant Proteins Enhances Adoption in In-Vivo Studies
    • Increasing Shift from Animal-Derived to Recombinant Alternatives Strengthens Ethical Sourcing Initiatives
    • Technological Advancements in CHO, E. coli, and Yeast Platforms Enhance Process Efficiency
    • Expansion of Functional Proteomics Research Generates Demand for Custom Recombinant Constructs
    • Proliferation of High-Throughput Screening Assays Sustains Demand for Consistent Protein Batches
    • Integration of AI and Machine Learning in Protein Engineering Improves Binding Affinity and Specificity
    • Rising Funding in Academic and CRO-Based Protein Research Supports Long-Term Market Growth
    • Adoption of Recombinant Enzymes in Industrial Bioprocessing Creates Commercial Opportunities
    • Intellectual Property Licensing for Proprietary Recombinant Proteins Spurs Strategic Collaborations
    • Tightening Regulatory Oversight on Protein Purity and Safety Boosts Demand for cGMP-Grade Variants
    • Global Expansion of Biomanufacturing Infrastructure Strengthens Regional Production and Distribution
    • Diversification of Recombinant Protein Therapeutic Portfolios Spurs Demand for Platform Flexibility
    • Sustained Investments in Vaccine Development and Infectious Disease R&D Propel Protein Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recombinant Proteins Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cytokines & Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Cytokines & Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immune checkpoint proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Immune checkpoint proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Virus Antigens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Virus Antigens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Enzymes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Recombinant Regulatory Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Recombinant Regulatory Protein by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Hormones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Hormones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Bacterial Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Bacterial Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Yeast & Fungi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Yeast & Fungi by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Insect Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Insect Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Host Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Other Host Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Mammalian systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Mammalian systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Therapeutics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Therapeutics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Pharma & Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World 6-Year Perspective for Pharma & Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 41: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 42: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 43: World 6-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 46: USA Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: USA 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 48: USA Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: USA 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 52: USA Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: USA 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 54: Canada Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Canada 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 58: Canada Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Canada 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 60: Canada Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Canada 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 64: Japan Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Japan 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 66: Japan Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Japan 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 70: China Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: China 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 72: China Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: China 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 76: China Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: China 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 78: Europe Recent Past, Current & Future Analysis for Recombinant Proteins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 79: Europe 6-Year Perspective for Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 82: Europe Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Europe 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 84: Europe Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Europe 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 88: France Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: France 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 90: France Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: France 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 94: France Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: France 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 96: Germany Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Germany 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 100: Germany Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Germany 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 102: Germany Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Germany 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 106: Italy Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Italy 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 108: Italy Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Italy 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 112: UK Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: UK 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 114: UK Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: UK 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 118: UK Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: UK 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 124: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of Europe 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 126: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of Europe 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Asia-Pacific 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 132: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Asia-Pacific 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 136: Rest of World Recent Past, Current & Future Analysis for Recombinant Proteins by Product - Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of World 6-Year Perspective for Recombinant Proteins by Product - Percentage Breakdown of Value Sales for Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones and Other Products for the Years 2025 & 2030
    • TABLE 138: Rest of World Recent Past, Current & Future Analysis for Recombinant Proteins by Host Cell - Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of World 6-Year Perspective for Recombinant Proteins by Host Cell - Percentage Breakdown of Value Sales for Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells and Mammalian systems for the Years 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Recombinant Proteins by Application - Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World 6-Year Perspective for Recombinant Proteins by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Drug Discovery & Development Application, Research Application and Other Applications for the Years 2025 & 2030
    • TABLE 142: Rest of World Recent Past, Current & Future Analysis for Recombinant Proteins by End-Use - Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Rest of World 6-Year Perspective for Recombinant Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotechnology Companies End-Use, Academic & Research Institutes End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION